Based on the remarkable findings uncovered by studies on melanoma and lung cancer, there have been a large number of studies exploring combined PD-(L)1 and CTLA-4 inhibition in other tumor types including MIBC, and PD-(L)1 inhibitors in combination with other immune checkpoints inhibitors. Here, CTLA4 is linked to melanoma.